Citigroup Inc Immuno Gen, Inc. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.46 - $29.95 $1.15 Million - $2.76 Million	92,192 Added 37.54%	337,743 $10 Million
Q3 2023 Nov 09, 2023	BUY	$14.09 - $19.87 $716,744 - $1.01 Million	50,869 Added 26.13%	245,551 $3.9 Million
Q2 2023 Aug 10, 2023	SELL	$3.75 - $20.05 $3.39 Million - $18.1 Million	-904,970 Reduced 82.3%	194,682 $3.67 Million
Q1 2023 May 11, 2023	BUY	$3.67 - $4.92 $1.82 Million - $2.44 Million	496,726 Added 82.39%	1,099,652 $4.22 Million
Q4 2022 Feb 09, 2023	SELL	$4.55 - $6.31 $1.37 Million - $1.9 Million	-301,572 Reduced 33.34%	602,926 $2.99 Million
Q3 2022 Nov 10, 2022	BUY	$4.48 - $6.47 $453,434 - $654,848	101,213 Added 12.6%	904,498 $4.32 Million
Q2 2022 Aug 10, 2022	BUY	$3.15 - $5.76 $1.95 Million - $3.57 Million	619,203 Added 336.37%	803,285 $3.61 Million
Q1 2022 May 12, 2022	SELL	$4.26 - $7.48 $894,314 - $1.57 Million	-209,933 Reduced 53.28%	184,082 $876,000
Q4 2021 Feb 10, 2022	SELL	$4.75 - $7.5 $275,077 - $434,332	-57,911 Reduced 12.81%	394,015 $2.93 Million
Q3 2021 Nov 10, 2021	BUY	$5.02 - $6.59 $2.27 Million - $2.98 Million	451,926 New	451,926 $2.56 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.